Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions

Lakhtakia, Ritu; Bharadwaj, Reena; Kumar, Vikesh; Mandal, Palash; Nema, Shrikant

doi:10.1016/s0377-1237(07)80145-6

Cited by 8 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was statistically significant difference in expression of HMWCK and P63 between cases of benign and malignant lesions prostate, indicated by P = 0.001. Similar findings were seen in the study by Shah et al , Singh et al [5892122] In our study, all cases were of benign prostatic hyperplasia.…”

Section: Discussionsupporting

confidence: 92%

Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm

Rathod

Jaiswal

Bindu

2019

J Family Med Prim Care

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm

Rathod

Jaiswal

Bindu

2019

J Family Med Prim Care

View full text Add to dashboard Cite

“…In our study, Ck34βE12 highlighted basal cells in 92.9% of cases of BPH, 72.9% of which showed intense cytoplasmic staining; but only one case (4%) showed weak discontinuous staining for this marker. This was close to the results of other studies conducted by Deepika et al, Shah et al,Lakhtakia et al,and Kotakidou et al (21,22,23,24).…”

Section: Discussionsupporting

confidence: 92%

“…This was close to the results of other studies conducted by Deepika et al , Shah et al, Lakhtakia et al ., and Kotakidou et al . ( 21 , 22 , 23 , 24 ).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR) Immunohistochemical Expression in Prostatic Lesions

2020

View full text Add to dashboard Cite

Scan to discover online Background & Objective: Some prostatic lesions contain small suspicious foci for prostatic carcinoma in which the morphological features are equivocal. Two immunohistochemical markers namely, cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR), were evaluated in these lesions for a definitive diagnosis and avoiding misdiagnosis or overdiagnosis of prostatic carcinoma. Methods: A total of 90 paraffin embedded blocks of prostatic tissue were selected and categorized into three groups as follows: 50 cases of benign prostatic hyperplasia (BPH), 20 cases of prostatic carcinoma, and 20 cases of benign prostatic lesions with suspicious foci labeled as ASAP (atypical small acinar proliferation) that occupy not more than 5% of the lesion. These cases were revised for histopathological diagnosis and stained with two immunohistochemical markers: Ck34βE12 and AMACR. Results: While 92.9% of BPH were positive for Ck34βE12, 96% of prostatic carcinoma were negative for this marker (P=0.0001). Regarding AMACR, 92.9% of BPH cases were negative, but 92% of prostatic carcinoma cases were positive for this marker (P=0.0001). Out of 20 cases of BPH, 15 cases containing suspicious foci showed Ck34βE12+/AMACR-(diagnosis: benign), but 5 cases were Ck34βE12-/AMACR+, for which the diagnosis changed to prostatic carcinoma (P=0.04). Conclusion: Immunohistochemical staining with Ck34βE12 and AMACR improved the diagnostic performance and increased confidence level for establishing definite diagnosis in cases with suspicious foci, in which the morphological features were equivocal. This could help to avoid misdiagnosis or overdiagnosis of prostatic carcinoma that would eventually improve the management of the patient and subsequently the prognosis.

show abstract

“…Benign prostatic hyperplasia (BPH) is a common urological condition in men. The prevalence of BPH increases from 20% at 40 years of age to 90% by the eighth decade of life [ 1 ]. Prostatic carcinoma is globally the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions

Garg

Kaur

Malhotra

et al. 2013

Prostate International

View full text Add to dashboard Cite

Purpose:Prostatic lesions on routine staining sometimes cause a diagnostic dilemma, especially when malignant tissue is limited and is mixed with benign prostatic glands or because of the presence of benign mimickers of carcinoma. The application of immunohistochemistry contributes a valuable differential diagnosis. This study aimed to evaluate a complete spectrum of various prostatic lesions and to supplement the histopathological diagnosis with immunohistochemistry in suspicious or atypical cases.Methods:A total of 364 consecutive prostatic specimens were evaluated. Routine hematoxylin and eosin staining and immunohistochemical staining against 34βE12 cytokeratin and proliferative marker (alpha-methylacyl-CoA-racemase, AMACR) were performed by use of the peroxidase antiperoxidase method.Results:Benign prostatic hyperplasia was the most frequent finding and involved 285 patients (78.3%). Prostatitis (majority nonspecific) formed the predominant subgroup in nonneoplastic lesions (n=119, 32.7%). The incidence of carcinoma was low (n=73, 20.1%). Of the 26 atypical or suspicious cases, 18 cases were positive for high molecular weight cytokeratin (high molecular weight cytokeratin, HMWCK) only, 4 cases were positive for AMACR only, and 4 cases showed positivity for both HMWCK and AMACR.Conclusions:Biopsy remains the gold standard. However, as an adjunct to biopsy, proliferative markers and basal cell markers have value for resolving suspicious or atypical cases.

show abstract

Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions

Cited by 8 publications

References 29 publications

Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm

Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm

Diagnostic Value of Cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR) Immunohistochemical Expression in Prostatic Lesions

Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions

Contact Info

Product

Resources

About